Bevacizumab and erlotinib in inoperable and metastatic hepatocellular carcinoma [liver cancer].
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jul 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.